Exela Tries To Escape Ruling, Nix Painkiller Patent Again

Law360, New York (December 3, 2013, 9:25 PM EST) -- Exela Pharma Sciences LLC and its subsidiaries asked a Delaware federal judge to reconsider a recent ruling that they infringed Cadence Pharmaceuticals Inc.’s patents by creating a generic version of injectable-painkiller Ofirmev, saying Monday that new evidence proved one of the patents invalid.

Following a seven day-bench trial, U.S. District Judge Leonard P. Stark ruled Nov. 14 that generic-drug maker Exela had infringed U.S. Patent Nos. 6,028,222 and 6,992,218, which protect the branded pain reliever Ofirmex. Stark also issued a permanent injunction barring the Exela defendants...
To view the full article, register now.